Cataract original papers on intracameral antibiotics and IOL power, a guideline-based case symposium, and ocular surface ...

At EURETINA 2026, Roger Goldberg, MD, MBA, explains why EYP-1901 missed LUGANO's primary endpoint despite matched anatomy, clean safety and a 42% cut in treatment burden. EyePoint's sustained-release ...

The Nobel Assembly at Karolinska Institutet announced that the 2026 Nobel Prize in Physiology or Medicine will be shared equally among Karl Deisseroth, MD, PhD, of the Howard Hugh ...

Ritesh Narula, MBBS, MS, discusses phase 1 and early phase 2 results of the Eyestem subretinal stem cell study in geographic atrophy, including an 11-letter mean visual acuity gain maintained at 18 ...

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with ...

Our FORCE experience with FYB-201 has been very encouraging. The original FORCE study provided multicentre real-world evidence across retinal vascular diseases, and our recent Middle Eastern extension ...

The American Academy of Ophthalmology (AAO) returns to New Orleans from October 9-12 for AAO 2026, with more than 20,000 ...

João Pedro Marques, MD, MSc, PhD, FEBOphth, an ophthalmic genetics and retina specialist from Coimbra, Portugal, spoke at the ...

Paul Nderitu, MBChB, MPhil, MBCS, FRCOphth, PhD, gives an update at EURETINA 2026 on Global RETFound, a foundation model ...

At EURETINA 2026, Elon van Dijk, MD, PhD, FEBOphth, reviewed trial evidence favouring half-dose PDT over micropulse laser and ...

Katherine Talcott, MD, discusses phase 2 VERONA results showing EYP-1901 plus aflibercept reduced supplemental treatment ...

Three studies presented at the 26th EURETINA Congress, taking place at the VIECON – Vienna Congress & Convention Center from ...